Lancet

2022 In Vitro Diagnostic eCommerce Business Models Growth Opportunities Report: Disruptive Differentiation in Supply Chain Management Drives New Growth Potential - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 18, 2022 - 9:46am

The "In Vitro Diagnostic eCommerce Business Models Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "In Vitro Diagnostic eCommerce Business Models Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • This study assesses the eCommerce business potential across sectors, creating resilient healthcare and diagnostic market opportunities for R&D, manufacturing, and supply chain functions.
  • It explores other scalable, cost-efficient business opportunities with new B2B products, customized outsourcing services, and technology-enabled tools for efficiency and ease of operations.
  • The study also examines the competitive environment, strategies, market models, and use cases for success in the IVD eCommerce platform industry.

Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent α- and β-Thalassemia

Retrieved on: 
Thursday, August 11, 2022 - 11:35pm

CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced that data from the core period of the open-label, Phase 2 study of PYRUKYND® (mitapivat) in adults with non-transfusion-dependent α- or β-thalassemia were published on August 11, 2022, in The Lancet. Data from this study were previously presented at the 2021 European Hematology Association (EHA) Annual Congress. PYRUKYND® is a first-in-class, investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase (PK) enzymes.

Key Points: 
  • Data from this study were previously presented at the 2021 European Hematology Association (EHA) Annual Congress.
  • PYRUKYND is a first-in-class, investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase (PK) enzymes.
  • These data demonstrate the potential clinical benefits of mitapivat for a broad spectrum of thalassemia patients and support its continued investigation in pivotal trials.
  • One patient who had -thalassemia discontinued after Week 4 due to a treatment-emergent adverse event deemed unrelated to the study drug.

Advanced Wound Care Market Report 2022-2030: Rising Incidences of Acute Diseases and Trauma Cases & Increased Geriatric Population Propel Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 9, 2022 - 3:08pm

Increasing prevalence of diabetes and pressure ulcers is expected to be one of the major drivers for advanced wound care market growth.

Key Points: 
  • Increasing prevalence of diabetes and pressure ulcers is expected to be one of the major drivers for advanced wound care market growth.
  • The major factor driving the growth of the market is rising incidences of acute diseases and trauma cases.
  • Moreover, increasing number of surgical procedures and growing geriatric population are also expected to support the growth of the market.
  • For this report, the publisher has segmented the global advanced wound care market based on product, wound type, end-use, and region:

eFFECTOR Therapeutics Appoints Douglas Warner, M.D., as Chief Medical Officer

Retrieved on: 
Monday, August 8, 2022 - 10:30am

SAN DIEGO and REDWOOD CITY, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced it has appointed Douglas Warner, M.D., as chief medical officer.

Key Points: 
  • SAN DIEGO and REDWOOD CITY, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced it has appointed Douglas Warner, M.D., as chief medical officer.
  • He will also be responsible for developing registration strategies for both programs and exploring expansion into additional oncology indications.
  • eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs.
  • eFFECTOR cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.

Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis

Retrieved on: 
Saturday, August 6, 2022 - 1:50am

MYFEMBREE offers an effective, once-daily treatment option for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.

Key Points: 
  • MYFEMBREE offers an effective, once-daily treatment option for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.
  • MYFEMBREE is available immediately to patients with moderate to severe pain associated with endometriosis with a prescription from their healthcare provider.
  • Myovant and Pfizer also are committed to supporting women in the U.S. who are prescribed MYFEMBREE throughout their treatment journeys.
  • Food and Drug Administration for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.

66% of diagnostic biopsies for common skin cancer can be avoided using Michelson Diagnostics' VivoSight OCT laser scanner

Retrieved on: 
Monday, August 1, 2022 - 12:00pm

It is the most common form of skin cancer that is rapidly increasing, with it affecting one in five people in the white population in their lifetime3.

Key Points: 
  • It is the most common form of skin cancer that is rapidly increasing, with it affecting one in five people in the white population in their lifetime3.
  • OCT is an advanced laser scanning tool which enables clinicians to non-invasively view below the surface of the skin at much higher resolutions than is possible with other technologies such as MRI or X-ray.
  • Michelson Diagnostics' VivoSight machine is already the world's leading scanner for the skin and has revolutionised how dermatologists conduct their treatment plans.
  • The study has proved that using the OCT can dramatically improve patient's physical care and treatment time.

66% of diagnostic biopsies for common skin cancer can be avoided using Michelson Diagnostics' VivoSight OCT laser scanner

Retrieved on: 
Monday, August 1, 2022 - 12:00pm

It is the most common form of skin cancer that is rapidly increasing, with it affecting one in five people in the white population in their lifetime3.

Key Points: 
  • It is the most common form of skin cancer that is rapidly increasing, with it affecting one in five people in the white population in their lifetime3.
  • OCT is an advanced laser scanning tool which enables clinicians to non-invasively view below the surface of the skin at much higher resolutions than is possible with other technologies such as MRI or X-ray.
  • Michelson Diagnostics' VivoSight machine is already the world's leading scanner for the skin and has revolutionised how dermatologists conduct their treatment plans.
  • The study has proved that using the OCT can dramatically improve patient's physical care and treatment time.

Terumo Blood and Cell Technologies collaborates with Eliaz Therapeutics in the development and commercialization of a novel therapeutic apheresis treatment for acute kidney injury (AKI)

Retrieved on: 
Wednesday, July 27, 2022 - 10:22pm

Terumo Blood and Cell Technologies specializes in a portfolio of technology, software and services for blood component collection, therapeutic apheresis and cellular technologies.

Key Points: 
  • Terumo Blood and Cell Technologies specializes in a portfolio of technology, software and services for blood component collection, therapeutic apheresis and cellular technologies.
  • Working with Terumo Blood and Cell Technologies could bring broad availability of this therapy to the global marketplace."
  • Terumo Blood and Cell Technologies' customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers and private medical practices.
  • Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology.

Extreme Heat & Climate Change Increase Risk of Malaria, other Health Threats

Retrieved on: 
Tuesday, July 26, 2022 - 5:48pm

Rising temperatures, changing rainfall patterns and extreme weather events are complicating efforts to eliminate malaria.

Key Points: 
  • Rising temperatures, changing rainfall patterns and extreme weather events are complicating efforts to eliminate malaria.
  • The same report projects those at risk of malaria infection could increase by 134 million by 2030 in South Asia.
  • "Extreme heat, severe weather, and increasing temperatures are wreaking havoc on our collective health and contributing to an alarming uptick in cases of mosquito-borne diseases worldwide," said Martin Edlund, Malaria No More CEO.
  • The President's Malaria Initiative also released its new five-year strategy in late 2021, highlighting the impact of climate change on global health and updating its strategic approach to reduce malaria mortality by adapting malaria services to "increase resilience against shocks," including Covid-19 and climate change.

Hygieia announces new CPT codes for autonomous insulin dose titration

Retrieved on: 
Tuesday, July 26, 2022 - 12:06pm

Hygieia, a digital therapeutics company for insulin therapy, announces the American Medical Association (AMA) CPT Editorial Panel has approved two new Category III codes for autonomous insulin dose titration, which can be used for Hygieias d-Nav Technology.

Key Points: 
  • Hygieia, a digital therapeutics company for insulin therapy, announces the American Medical Association (AMA) CPT Editorial Panel has approved two new Category III codes for autonomous insulin dose titration, which can be used for Hygieias d-Nav Technology.
  • d-Nav is the first FDA-cleared technology to autonomously adjust insulin dose recommendations to correspond to a patients changing insulin needs.
  • These new codes acknowledge the important role digital therapeutics play in medicine today, said Eran Bashan, Ph.D., Hygieia co-founder and board chairman.
  • The two codes are:
    0740T Remote, autonomous algorithm-based recommendation system for insulin dose calculation and titration; initial set-up and patient education.